Johnson & Johnson (NYSE:JNJ) Shares Acquired by Calamos Wealth Management LLC

Calamos Wealth Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 50.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,741 shares of the company's stock after acquiring an additional 10,280 shares during the quarter. Calamos Wealth Management LLC's holdings in Johnson & Johnson were worth $4,818,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Keener Financial Planning LLC bought a new position in Johnson & Johnson in the fourth quarter worth $40,000. Tower View Wealth Management LLC raised its holdings in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock worth $40,000 after purchasing an additional 165 shares in the last quarter. Creative Capital Management Investments LLC raised its holdings in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company's stock worth $45,000 after purchasing an additional 86 shares in the last quarter. Altshuler Shaham Ltd raised its holdings in Johnson & Johnson by 37.8% in the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company's stock worth $49,000 after purchasing an additional 87 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. raised its holdings in Johnson & Johnson by 216.7% in the third quarter. Mizuho Securities Co. Ltd. now owns 380 shares of the company's stock worth $59,000 after purchasing an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Royal Bank of Canada reduced their price target on Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 17th. Bank of America reduced their price target on Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Morgan Stanley reduced their price target on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a report on Wednesday, April 17th. Finally, Raymond James increased their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an "outperform" rating in a research report on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $175.86.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company's stock, valued at approximately $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.69 on Friday, hitting $146.13. The stock had a trading volume of 6,182,425 shares, compared to its average volume of 7,378,293. The stock has a market cap of $352.14 billion, a price-to-earnings ratio of 9.11, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The business's 50-day simple moving average is $155.26 and its two-hundred day simple moving average is $155.32. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts' expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the firm posted $2.68 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date is Monday, May 20th. Johnson & Johnson's payout ratio is presently 29.68%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.